Assessing the effectiveness of a new protocol for Hepatitis C-Genotype 1 Treatment for Veterans

2.50
Hdl Handle:
http://hdl.handle.net/10755/308165
Category:
Abstract
Type:
Presentation
Title:
Assessing the effectiveness of a new protocol for Hepatitis C-Genotype 1 Treatment for Veterans
Author(s):
Longo, Bernadette M.; King, Elizabeth Ann; Baxter, Kimberly
Lead Author STTI Affiliation:
Nu Iota
Author Details:
Bernadette M. Longo, PhD, RN, CNL, longo@unr.edu; Elizabeth Ann King, MSN, RN, CNL; Kimberly Baxter, MSN, RN, FNP-BC
Abstract:

Poster presented on: Monday, November 18, 2013, Tuesday, November 19, 2013

Previous treatment for hepatitis C infection (HCV) has been poorly tolerated by patients because of considerable side effects, and a long treatment time which provided only a 50% cure rate.  In 2011, the Veterans Administration approved the addition of Telaprevir or Boceprevir to the treatment regime of Peg Interferon and Ribavirin for Veterans with HCV genotype 1. The purpose of this Clinical Nurse Leader (CNL) project was to assess the effectiveness of the new treatment protocol provided by the treatment team in an outpatient microsystem.  A retrospective cohort design compared treatment outcomes from inclusive groups of Veteran HCVgen-1 patients (N = 59) for 20 months prior to start of the new treatment to 9 months time with the new protocol. Outcome measures included: viral load in the bloodstream taken at baseline and weeks 4, 8, 12, and 24; cure rates; total treatment time; and attrition.  Results revealed that although the new treatment cohort had over twice the viral load at baseline, they had a 9% higher cure rate (57% vs. 66%), more rapid decrease in viral load (p<0.001; negligible at 8 weeks), and less patient attrition. Moreover, a further comparison between cohort patients with first-time treatment for HCV showed a significantly higher cure rate of 86% with the new treatment protocol. Cost analysis of the new HCV treatment protocol estimated an additional $15,000-$37,000 per patient. Regardless, the new protocol is in alignment with the mission of the institution and improvement in clinical outcomes was attained. This evidence-based practice project demonstrates the utility of the emerging CNL role within today’s healthcare team.
Keywords:
Hepatitis C; Telaprevir; Boceprevir
Repository Posting Date:
19-Dec-2013
Date of Publication:
19-Dec-2013
Conference Date:
2013
Conference Name:
42nd Biennial Convention
Conference Host:
Sigma Theta Tau International, the Honor Society of Nursing
Conference Location:
Indianapolis, Indiana, USA
Description:
42nd Biennial Convention 2013 Theme: Give Back to Move Forward. Held at the JW Marriott
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission.

Full metadata record

DC FieldValue Language
dc.language.isoen_USen_GB
dc.type.categoryAbstracten_GB
dc.typePresentationen_GB
dc.titleAssessing the effectiveness of a new protocol for Hepatitis C-Genotype 1 Treatment for Veteransen_GB
dc.contributor.authorLongo, Bernadette M.en_GB
dc.contributor.authorKing, Elizabeth Annen_GB
dc.contributor.authorBaxter, Kimberlyen_GB
dc.contributor.departmentNu Iotaen_GB
dc.author.detailsBernadette M. Longo, PhD, RN, CNL, longo@unr.edu; Elizabeth Ann King, MSN, RN, CNL; Kimberly Baxter, MSN, RN, FNP-BCen_GB
dc.identifier.urihttp://hdl.handle.net/10755/308165-
dc.description.abstract<p>Poster presented on: Monday, November 18, 2013, Tuesday, November 19, 2013</p>Previous treatment for hepatitis C infection (HCV) has been poorly tolerated by patients because of considerable side effects, and a long treatment time which provided only a 50% cure rate.  In 2011, the Veterans Administration approved the addition of Telaprevir or Boceprevir to the treatment regime of Peg Interferon and Ribavirin for Veterans with HCV genotype 1. The purpose of this Clinical Nurse Leader (CNL) project was to assess the effectiveness of the new treatment protocol provided by the treatment team in an outpatient microsystem.  A retrospective cohort design compared treatment outcomes from inclusive groups of Veteran HCVgen-1 patients (N = 59) for 20 months prior to start of the new treatment to 9 months time with the new protocol. Outcome measures included: viral load in the bloodstream taken at baseline and weeks 4, 8, 12, and 24; cure rates; total treatment time; and attrition.  Results revealed that although the new treatment cohort had over twice the viral load at baseline, they had a 9% higher cure rate (57% vs. 66%), more rapid decrease in viral load (p<0.001; negligible at 8 weeks), and less patient attrition. Moreover, a further comparison between cohort patients with first-time treatment for HCV showed a significantly higher cure rate of 86% with the new treatment protocol. Cost analysis of the new HCV treatment protocol estimated an additional $15,000-$37,000 per patient. Regardless, the new protocol is in alignment with the mission of the institution and improvement in clinical outcomes was attained. This evidence-based practice project demonstrates the utility of the emerging CNL role within today’s healthcare team.en_GB
dc.subjectHepatitis Cen_GB
dc.subjectTelapreviren_GB
dc.subjectBocepreviren_GB
dc.date.available2013-12-19T17:27:45Z-
dc.date.issued2013-12-19-
dc.date.accessioned2013-12-19T17:27:45Z-
dc.conference.date2013en_GB
dc.conference.name42nd Biennial Conventionen_GB
dc.conference.hostSigma Theta Tau International, the Honor Society of Nursingen_GB
dc.conference.locationIndianapolis, Indiana, USAen_GB
dc.description42nd Biennial Convention 2013 Theme: Give Back to Move Forward. Held at the JW Marriotten_GB
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission.en_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.